Constantiam Biosciences
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Constantiam Biosciences is a precision medicine company translating deep mutational scanning and machine learning into breakthrough therapies for severe genetic disorders. Leveraging our proprietary high-throughput functional genomics platforms, RareScan and MAVEvidence, we rapidly decode human genetic variation to discover and optimize targeted small molecules. Our lead pipeline asset is CB-001, a first-in-class oral pharmacological chaperone designed to cross the blood-brain barrier to treat Gaucher Disease Type 3 and GBA-associated Parkinson’s disease (GBA-PD). By stabilizing misfolded glucocerebrosidase (GBA) variants, CB-001 restores lysosomal function and addresses profound unmet needs in neurodegenerative and orphan disorders. Backed by extensive variant-effect mapping, our pipeline aims to structurally derisk precision drug development from target discovery through patient stratification.
Company HQ City:
Watertown
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
CB-001, first-in-class pharmacological chaperone
CEO
Nicholas Schafer
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
January 2027
What is your next catalyst (value inflection) update?
Drug nomination, completion of IND-enabling studies and regulatory submission for CB-001, and Initiation of Phase 1 clinical trials for CB-001 in Gaucher Disease Type 3..
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}